Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Marqibo

 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Vincristine sulfate liposomevincristine liposome
vincristine liposome Injection [Marqibo]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias.
BACKGROUND Vincristine sulfate liposome injection (VSLI; Marqibo®) is an encapsulated preparation of standard vincristine in… Expand
  • table I
  • table III
  • table III
  • table IV
  • figure 1
Is this relevant?
2015
2015
Plasma Vincristine Levels Are 100-Fold Higher with Marqibo® (Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients ≥ 60 Years Old with Newly…
Background: Marqibo® (vincristine sulfate LIPOSOME injection, VSLI) is currently approved in the US for treatment of adults with… Expand
Is this relevant?
2014
2014
Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative…
BACKGROUND VSLI (Marqibo) is active in advanced non-Hodgkin lymphoma (NHL) and untreated aggressive NHL. Because of its favorable… Expand
  • table 1
  • table 2
  • table 5
  • table 3
  • figure 1
Is this relevant?
2013
2013
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with…
Vincristine sulfate liposome injection (VSLI; Marqibo(®) ; M) is active in relapsed and refractory lymphomas, and approved in the… Expand
  • table I
  • table II
  • table III
  • figure 1
  • table IV
Is this relevant?
2012
2012
FDA approves liposomal vincristine (Marqibo) for rare leukemia.
The FDA has approved vincristine sulfate liposome injection (Marqibo) to treat adults with Philadelphia chromosome–negative acute… Expand
Is this relevant?
2011
2011
Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function.
Marqibo (vincristine sulfate liposome injection, VSLI) is a novel liposomal formulation of vincristine sulfate (VCR) being… Expand
  • table I
  • table II
  • table III
  • table IV
Is this relevant?
2010
2010
Phase II study of marqibo in adult patients with refractory or relapsed philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL).
6507 Background: Management of adult ALL patients who relapse is challenging due to highly drug resistant disease and frequent… Expand
Is this relevant?
Review
2009
Review
2009
Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study.
BACKGROUND Marqibo, a sphingosomal/cholesterol encapsulation of vincristine sulfate has targeted, increased, and sustained… Expand
Is this relevant?
2009
2009
Phase II study of vincristine sulfate liposomes injection in patients with metastatic uveal melanoma.
9067 Background: Preclinical and clinical studies showed that liposomal encapsulation of vincristine sulfate (VCR) results in… Expand
Is this relevant?
2007
2007
Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) Concentrates Vincristine in Tumor Tissue and Lymphoid Malignancy Oriented Tissues in Tumor-Bearing Mice.
Background: Vincristine sulfate (VCR) is a cell-cycle specific, lipophilic, anti-cancer drug that inhibits cell division by… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE